Skip to main content

Advertisement

Table 1 Characteristics of trials included in meta-analyses

From: Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes

  STOP-NIDDM (n = 1429) Voglibose Ph-3 (n = 1778) ABC (n = 859) ACE (n = 6522) UKPDS (n = 1946)
Year published 2002 2009 2017 2017 1998
Recruitment dates December 1995–July 1998 October 2003–March 2007 May 2005–June 2012 March 2009–October 2015 May 1994–September 1994
Dose 100 mg three times daily 0.2 mg three times daily 0.2 mg three times daily 50 mg three times daily 100 mg three times daily
Inclusion criteria Impaired glucose tolerance Impaired glucose tolerance Impaired glucose tolerance and previous MI Impaired glucose tolerance and established coronary heart disease N/A
Cardiovascular outcome Coronary heart diseasea, CVD death, congestive heart failure, cerebrovascular events and peripheral vascular disease N/A CVD composite endpointb MACE- 5c MACE-5c
Diabetes outcome New-onset diabetes New-onset diabetes N/A New-onset diabetes N/A
  1. Data are mean ± 1 SD or median (IQR)
  2. aMyocardial infarction, new angina, revascularization procedures
  3. bCV death, non-fatal MI, Non-fatal unstable angina, non-fatal stroke, coronary revascularization procedure
  4. cCV-death, non-fatal stroke, non-fatal MI, hospitalization for unstable angina and hospitalization for heart failure
  5. NB: Diabetes was diagnosed when two successive diagnostic plasma glucose values of either FPG ≥ 7·0 mmol/L or 2hrPG ≥ 11·1 mmol/L was obtained
  Acarbose (n = 714) Placebo (n = 715) Voglibose (n = 897) Placebo (n = 881) Voglibose (n = 424) Placebo (n = 435) Acarbose (n = 3272) Placebo (n = 3250) Acarbose (n = 973) Placebo (n = 973)
Age (years) 54.3 ± 7.9 54.6 ± 7.9 55.7 ± 9.1 55.7 ± 9.2 67 (57, 73) 65 (58, 73) 64.4 ± 8.2 64.3 ± 8.0 60 ± 9 60 ± 9
BMI (Kg/m2) 31.0 ± 4.3 30.9 ± 4.2 25.8 ± 3.7 25.9 ± 3.8 24.2 (22.5, 26.0) 24.3 (22.5,26.3) 25.3 ± 3.1 25.5 ± 3.1 29.8 ± 5.6 29.6 ± 5.7
Female 353 (52%) 342 (50%) 356 (40%) 351 (40%) 60 (14.2%) 58 (13.3%) 877 (27%) 885 (27%) 369 (37.9%) 344 (35.4%)
  1. Data are mean ± 1 SD or median (IQR)
  2. aMyocardial infarction, new angina, revascularization procedures
  3. bCV death, non-fatal MI, Non-fatal unstable angina, non-fatal stroke, coronary revascularization procedure
  4. cCV-death, non-fatal stroke, non-fatal MI, hospitalization for unstable angina and hospitalization for heart failure
  5. NB: Diabetes was diagnosed when two successive diagnostic plasma glucose values of either FPG ≥ 7·0 mmol/L or 2hrPG ≥ 11·1 mmol/L was obtained